EGFR and ovarian mucinous adenocarcinoma: This study revealed that EGFR may have a role as a prognostic marker in ovarian cancer which was not evident in previous studies.26 Based on the outcomes of this study, further investigation of erlotinib in the treatment of mucinous ovarian carcinoma is not warranted.